Auto-hematopoietic stem cell transplantation or chemotherapy? Meta-analysis of clinical choice for AML.

Autor: Ge S; First Clinical College, China Medical University, Shenyang, Liaoning Province, China., Wang J; Second Clinical College, China Medical University, Shenyang, Liaoning Province, China., He Q; Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China., Zhu J; Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China., Liu P; Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China., Wang H; Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China. wanght@si-hospital.org., Zhang F; Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China. zhf935@163.com.
Jazyk: angličtina
Zdroj: Annals of hematology [Ann Hematol] 2024 Oct; Vol. 103 (10), pp. 3855-3866. Date of Electronic Publication: 2024 Jan 25.
DOI: 10.1007/s00277-024-05632-z
Abstrakt: For patients with acute myeloid leukemia (AML) who are not candidates for allogeneic stem cell transplantation (SCT) or do not have a human leukocyte antigen (HLA)-matched donor, it is unclear whether autologous SCT (ASCT) has a better prognosis after the first complete response (CR1) compared to further chemotherapy treatment. A meta-analysis evaluating ASCT compared to further chemotherapy for AML patients in CR1 was performed. The Medline, Embase, Cochrane Controlled Trials Registry, Cochrane Library, Web of Science, and National Knowledge Infrastructure of China databases were searched for relevant literature as of May 26, 2023. Eligible studies included prospectively enrolled adults with AML and randomized first-time respondent patients who did not have a matched sibling donor. Fourteen randomized controlled trials were identified and included 4281 participants, of which 1499 patients received ASCT and 2782 underwent chemotherapy and continued follow-up. In patients with AML in CR1, a lower relapse rate was associated with ASCT compared to chemotherapy [odds ratio (OR) = 0.49, 95% confidence interval (CI) = 0.41-0.57]. Significant disease-free survival (DFS; OR = 1.37, 95% CI = 1.02-1.84) and relapse-free survival (RFS; OR = 2.78, 95% CI = 1.28-6.02) ASCT benefits were documented, and there was no difference in the overall survival (OS) when the studies were pooled (OR = 1.12, 95% CI = 0.85-1.48). The study results indicated that after the first remission, AML patients receiving autologous stem cell transplantation had higher DFS and RFS, similar OS, and lower relapse compared to patients undergoing chemotherapy treatment. This indicated that autologous stem cell transplantation may have a better prognosis.
(© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: